Cost-Effectiveness Analysis of Prostate Specific Antigen Screening Among Chinese Men

Abstract

 

In the main text and Table 4 of the baseline results, there were 3 numerical discrepancies related to the decimal points. The figures for the costs of the clinical diagnostic strategy, the population-based screening strategy, and the incremental cost need to be shifted one decimal place forward. The corrected amounts are 36,985,783.05 CNY for the clinical diagnostic strategy, 48,069,831.44 CNY for the population-based screening strategy, and 11,084,048.38 CNY for the incremental cost of the population-based screening strategy.

Authors

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×